64473-35-4

Basic information

• Product Name: 1-(3-bromopropyl)-4-chlorobenzene
• Synonyms: 1-(3-bromopropyl)-4-chlorobenzene;1-Chloro-4-(3-bromopropyl)benzene;3-(4-Chlorophenyl)-1-bromopropane;3-(4-Chlorophenyl)propyl bromide
• CAS NO: 64473-35-4
• Molecular Formula: C₉H₁₀BrCl
• Molecular Weight: 233.5327
• Mol File: 64473-35-4.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 92 °C(Press: 0.3 Torr)
• Appearance: /
• Density: 1.424
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 1-(3-bromopropyl)-4-chlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-bromopropyl)-4-chlorobenzene(64473-35-4)
• EPA Substance Registry System: 1-(3-bromopropyl)-4-chlorobenzene(64473-35-4)

Safety Data

• Hazardous Substances Data: 64473-35-4(Hazardous Substances Data)

Usage

General Description

1-(3-bromopropyl)-4-chlorobenzene is a synthetic, organic compound that is part of the halogenated hydrocarbon group of chemicals, featuring both a bromine and chlorine atom in its structure. It's characterized by a benzene ring with a chlorine atom substitution at the fourth position and a three carbon alkyl chain at the first position, which is then substituted by a bromine atom. This chemical is generally used as a precursor or intermediate in the synthesis of other more complex organic compounds such as pesticides, pharmaceuticals, and dyes. It is typically synthesized through a multi-step organic reaction using bromine and propyl chloride as key reactants. There are potential hazards associated with this compound, which include skin, eye, and respiratory irritation, due to its reactive nature and volatility.

Upstream product

• 106-39-8 bromochlorobenzene 
• 109-64-8 1,3-dibromo-propane 
• 1798-84-1 1-chloro-4-cyclopropylbenzene 
• 6282-88-8 3-(p-chlorophenyl)propanol 
• 558-13-4 carbon tetrabromide 
• 2019-34-3 3-(4-chlorophenyl)propanoic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 20754-21-6 methyl 3-(4-chlorophenyl)propenoate 
• 7116-36-1 ethyl 3-(4-chlorophenyl)propanoate 
• 24393-52-0 ethyl (E)-3-(4-chlorophenyl)prop-2-enoate 
• 1615-02-7 3-(4-chlorophenyl)prop-2-enoic acid 
• 6529-53-9 1-(2-bromoethyl)-4-chlorobenzene 
• 37556-13-1 diethyl (4-chlorobenzyl)malonate 

Downstream Products

• 175219-67-7 3-(4-chlorophenyl)propane-1-thiol 
• 18655-50-0 3-(4-chlorophenyl)propylamine 
• 1338684-95-9 N-[3-(4-chlorophenyl)propyl]-4-methyl-3-nitroaniline 
• 1338684-96-0 N₁-[3-(4-chlorophenyl)propyl]-4-methylbenzene-1,3-diamine 
• 1338684-97-1 8-amino-10-[3-(4-chlorophenyl)propyl]-7-methylbenzo[g]pteridine-2,4(3H,10H)-dione 
• 1338684-94-8 N-{10-[3-(4-chlorophenyl)propyl]-7-methyl-2,4-dioxo-2,3,4,10-tetrahydrobenzo[g]-pteridin-8-yl}propanamide 
• 112298-30-3 5-(p-chlorophenyl)-1,1,1-trifluoropentan-2-one 
• 112887-55-5 2-acetylaminomethyl-4-[3-(4-chlorophenoxy)propyl]morpholine 
• 86373-91-3 4-[3-(4-Chloro-phenyl)-propylamino]-phthalic acid diethyl ester 
• 86373-87-7 {4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-acetic acid ethyl ester 
• 86373-85-5 3-[3-(4-Chloro-phenyl)-propylamino]-benzoic acid ethyl ester 

Relevant articles and documents

B(C6F5)3-Catalyzed Diastereoselective Formal (4 + 1)-Cycloaddition of Vinylcyclopropanes and Et2SiH2

A formal (4 + 1)-cycloaddition of vinylcyclopropanes and Et2SiH2 to afford 3,4-disubstituted silolanes is reported. The reaction sequence commences with the known B(C6F5)3-catalyzed alkene hydrosilylation with dihydrosilanes. Cleavage of the remaining Si-H bond in the hydrosilylation product assisted by B(C6F5)3 leads to formation of a cyclopropane-stabilized silylium ion. The activated cyclopropane ring is then opened by the in situ-generated borohydride accompanied by ring closure to the silolane. The diastereoselectivity is rationalized by a mechanistic model.

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity

The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(–)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM3R). Compared to 1 and 5, (R)-(–)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(–)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(–)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.